← Back to Insights
February 14, 2019
Authors
David Burda
Topics
Economics Outcomes Policy
Channels
Blogs

Price Controls Take Root in Rhode Island. Will They Spread to Your State?

One state’s attempt to control healthcare costs by using “affordability standards” ended up limiting increases in commercial health insurance payments to hospitals and doctors without any changes in utilization or clinical outcomes.

That’s good news if you’re a commercial health insurer or a patient who gets their health benefits from a commercial health insurer. That’s bad news if you’re a hospital or doctor who’s now getting paid less than expected for producing the same clinical and financial outcomes.

This lesson in what happens when healthcare competition fails and rate regulation takes over is brought to you by the state of Rhode Island. The Ocean State’s experience with price controls is the subject of a new study in Health Affairs.

Researchers from Stanford and Harvard studied the impact of Health Insurance Affordability Standards imposed by Rhode Island’s Office of the Health Insurance Commissioner in 2010. The standards do a lot of things to “encourage” hospitals and doctors to enter into value-base reimbursement contracts with commercial insurers.

Encouragement comes in the form of an annual cap on price increases for both inpatient and outpatient services. Price increases in Rhode Island are limited to changes in the Medicare price index for inpatient and outpatient care plus 1 percent. So, if Medicare payments go up 2 percent, Rhode Island limits commercial health insurance payment increases to hospitals and doctors to 3 percent.

The researchers wanted to know how the affordability standards affected how much commercial health carriers spent on patient care services.

The researchers’ unit of measure was the change in the quarterly per enrollee fee-for-service medical spending by the health insurers. The researchers’ study period was 2007 through 2016. They compared FFS spending on 38,001 adults age 27-64 in Rhode Island over that 10-year span with a matched pool of 38,001 enrollees in other states.

Here’s what they found, from 2010 through 2016:

  • Rhode Island insurers spent an average of $76 less per quarter per enrollee for all FFS care compared with their peers in other states.
  • Rhode Island insurers spent an average of $39 less per quarter per enrollee for FFS inpatient care compared with their peers in other states.
  • Rhode Island insurers spent an average of $36 less per quarter per enrollee for FFS outpatient care compared with their peers in other states.

There was no significant change in utilization of inpatient and outpatient services over the study period. And there was no significant change in clinical outcomes other than a reduced use of imaging scans by Rhode Island providers on patients with uncomplicated headaches.

“The decline in spending growth was driven by lower prices, rather than reduced utilization,” the study said.

The more interesting conclusion by the researchers from a market-based reform perspective was this: “In instituting price inflation caps…the state-mandated affordability standards appear to have shifted the negotiation dynamics between commercial insurers and providers in favor of insurers.”

I know what you’re thinking. Rhode Island is different. It’s a small state with a small number of hospitals. (The Hospital Association of Rhode Island counts 11 hospitals as members. Ocean’s 11? ) The healthcare market dynamics are different. There’s no way that could happen in my state.

You keep thinking that as more hospitals and health systems merge and more attention keeps getting heaped on rising hospital prices like that other recent study in Health Affairs and this piece this week in the New York Times.

Wouldn’t it be better to let free market competition rather than a state agency set healthcare prices? If you’re not careful, you could end up with a complicated headache.

Author

David Burda is a columnist for 4sight Health and news editor of 4sight Friday, our weekly newsletter. Follow Burda on Twitter @DavidRBurda and on LinkedIn. Read his bio here

About the Author

David Burda

David Burda began covering healthcare in 1983 and hasn’t stopped since. Dave writes this monthly column “Burda on Healthcare,” contributes weekly blog posts, manages our weekly newsletter 4sight Friday, and hosts our weekly Roundup podcast. Dave believes that healthcare is a business like any other business, and customers — patients — are king. If you do what’s right for patients, good business results will follow.

Dave’s personnel experiences with the healthcare system both as a patient and family caregiver have shaped his point of view. It’s also been shaped by covering the industry for 40 years as a reporter and editor. He worked at Modern Healthcare for 25 years, the last 11 as editor.

Prior to Modern Healthcare, he did stints at the American Medical Record Association (now AHIMA) and the American Hospital Association. After Modern Healthcare, he wrote a monthly column for Twin Cities Business explaining healthcare trends to a business audience, and he developed and executed content marketing plans for leading healthcare corporations as the editorial director for healthcare strategies at MSP Communications.

When he’s not reading and writing about healthcare, Dave spends his time riding the trails of DuPage County, IL, on his bike, tending his vegetable garden and daydreaming about being a lobster fisherman in Maine. He lives in Wheaton, IL, with his lovely wife of 40 years and his three children, none of whom want to be journalists or lobster fishermen.

Recent Posts

Economics
AMA Draws Blood With Policy on Hospital Tax Exemptions
There are certain lines you don’t cross, even when you point the finger at another healthcare industry sector… Read More
By November 20, 2024
System Dynamics
Burda on Healthcare: It’s Open Season on Employer Benefits Surveys
It’s that time of year when people choose their health insurance benefits and select a health plan. Not… Read More
By November 12, 2024
Economics
It’s Big Pharma’s Turn to Point the Finger
It’s time for another installment of my healthcare blame game series. The series is based on my theory… Read More
By November 6, 2024